Stock DYN DYNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Real-time Estimate Cboe BZX
Other stock markets
 20:59:49 10/05/2024 BST 		5-day change 1st Jan Change
26.02 USD +0.27% Intraday chart for Dyne Therapeutics, Inc. +0.05% +96.18%
05-02 Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target
MT
Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating
MT
Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating
MT
Stifel Adjusts Price Target on Dyne Therapeutics to $41 From $35, Maintains Buy Rating
MT
Oppenheimer Adjusts Dyne Therapeutics Price Target to $47 From $44, Maintains Outperform Rating
MT
H.C. Wainwright Initiates Dyne Therapeutics With Buy Rating, Price Target is $36
MT
Raymond James Adjusts Price Target on Dyne Therapeutics to $56 From $27, Keeps Strong Buy Rating
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Traders Await Rate Cut Hints in Policy Meeting Readout
MT
Chardan Adjusts Price Target on Dyne Therapeutics to $20 From $17, Maintains Buy Rating
MT
Raymond James Upgrades Dyne Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $27 From $16
MT
Oppenheimer Initiates Coverage on Dyne Therapeutics With Outperform Rating, $34 Price Target
MT
Guggenheim Starts Dyne Therapeutics at Buy With $33 Price Target
MT
JPMorgan Adjusts Price Target on Dyne Therapeutics to $18 From $24, Maintains Overweight Rating
MT
Raymond James Adjusts Price Target on Dyne Therapeutics to $16 From $15, Maintains Outperform Rating
MT
Chardan Research Initiates Coverage on Dyne Therapeutics With Buy Rating, $17 Price Target
MT
Raymond James Starts Dyne Therapeutics at Outperform With $15 Price Target
MT
Piper Sandler Lowers Dyne Therapeutics' Price Target to $12 From $16, Maintains Overweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DYN Stock
  4. News Dyne Therapeutics, Inc.
  5. Analyst Reco.